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Abstract
Background: A novel magnetic resonance imaging (MRI)-conditional coupling system was developed that
accommodates a focused ultrasound (FUS) transducer. With this coupling system, the transducer can access
targets from top to bottom. The intended clinical application is treatment of fibroids using FUS with the patient
placed in supine position.
Methods: The coupling system was manufactured using a rapid prototyping device using acrylonitrile butadiene
styrene (ABS) plastic. Coupling to a gel phantom was achieved using a water bag filled with degassed water. The
FUS transducer was immersed in the water bag.
Results: The coupling system was successfully tested for MRI compatibility using fast-gradient pulse sequences in
a gel phantom. The robotic system with its new coupling system was evaluated for its functionality for creating
discrete and multiple (overlapping) lesions in the gel phantom.
Conclusions: An MRI-conditional FUS coupling system integrated with an existing robotic system was developed
that has the potential to create thermal lesions in targets using a top-to-bottom approach. This system has the
potential to treat fibroid tumors with the patient lying in supine position.
Keywords: Ultrasound, Robot, MRI, Fibroid, Cancer
Background
The available main treatment options for uterine fibroids
include hysterectomy, myomectomy, and uterine artery
embolization. Hysterectomy is the primary option for
resolving fibroid-associated symptoms. Uterine artery
embolization (UAE) is major treatment option for fibroids
which was introduced in 1995 [1]. This treatment option
involves femoral artery catheterization and intra-arterial
infusion of embolization particles. As a result, UAE
produces ischemia of the fibroid uterus, thus reducing sig-
nificantly the volume of fibroids [1]. Another treatment
option for uterine fibroids involves hormonal manipula-
tion. Gonadotrophin-releasing hormone (GnRH) is pre-
dominantly used for the temporary reduction of fibroid
volume by as much as 60% sometimes [2].
Another treatment option which is not widely ac-
cepted is cryoablation [3]. With cryoablation, the uterine
fibroid is cooled to very low temperatures. This option is
introduced using either laparoscopic or hysteroscopic
access [4, 5].
Another option deployed recently is magnetic reson-
ance imaging-guided focused ultrasound (MRgFUS) [6].
MRgFUS is an effective and completely noninvasive
modality. MRgFUS may be used as a fertility-preserving
option for some cases. The first treatment of uterine
fibroids using MRgFUS was performed in 2003 and was
implemented by Stewart and colleagues [6]. The results
of this study were promising, and thus lead to additional
clinical trials. The goal of the additional trials was to
evaluate the efficacy of MRgFUS in larger number of
patients. These studies showed significant reduction of
clinical symptoms. Additionally, improvement in life
quality was reported at 6, 12, and 24 months. Until now,
more than 8500 patients have been treated with MRgFUS
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worldwide. Only few side effects were reported [7]. The
acceptance rates from patients are evaluated as high [7].
In recent reports of clinical trials, with proper selection of
patient population, the reduction in volume is often more
than 50% [8]. However, despite the good clinical results,
one of the disadvantages of this procedure is the lengthy
procedure time (i.e., low time efficiency) which is a big
problem when treating large fibroids.
The first MRgFUS commercial system (Exablate) to be
used for the treatment of fibroids was developed by
InSightec (Tirat Carmel, Israel) [9]. The system uses a
phased-array transducer operating close to 1 MHz. The
transducer is positioned close to the target using a robotic
system. The whole system is placed in the magnetic reson-
ance imaging (MRI) table. Treatment is performed with
the patient in the prone position and under light sedation,
with active monitoring of vital signs.
In 2009, Philips developed the MRgFUS robotic sys-
tem (Sonalleve, Philips Healthcare) that was Conformité
Européenne (CE)-marked for the treatment of uterine
fibroids [10, 11]. Treatments were performed using a
phased-array 256-channel transducer (radius of curva-
ture 12 cm, aperture 13 cm; operable at 1.2 MHz)
equipped with a mechanical displacement device with
5 degrees of freedom (three linear and two angular).
This system is able to perform volumetric ablation. With
this system, the patient is also placed in prone position.
This study includes the conversion of a robotic system
intended for brain applications to a robotic system that
can be used for accessing fibroids. This is achieved by
modifying the coupling system, thus allowing top-to-
bottom coupling (axial in MRI). The system was evalu-
ated in a gel phantom for producing discrete and over-
lapping lesions. The system uses a single-element
transducer, which makes the system less complex and




An existing positioning device with three axes (X, Y, Z)
was used [12]. Figure 1 shows the existing robotic sys-
tem dedicated for the brain. The coupling system was
modified so that top-to-bottom access was possible. A
modified arm was developed that was inserted in a
coupling structure that makes coupling to fibroids (in
this study, gel phantom). The three axes were driven by
piezoelectric ultrasonic motors (USR60-S3N, Shinsei
Kogyo Corp., Tokyo, Japan). Optical encoders were used
(US Digital Corporation, Vancouver, WA 98684, USA).
The encoder output was connected to the counter input
of a data acquisition board USB 6251 (NI, Austin, USA).
Figure 2 shows the developed coupling that can be used
for a top-to-bottom access of ultrasound to targets. This
prototype coupling system includes a transducer arm
which is connected to the Z-axis, a holder for the water
bag, and a base that holds the water bag holder. This
coupling system is manually positioned to the patient.
This structure includes a movable water bag (steps of
1 cm), a transducer holder, and an arm that is fixed to
the existing robot. Figure 3 shows the concept of using
the modified robotic system for access to the fibroids.
Experimental setup
The arm of the robotic system with the 1-MHz transducer
was immersed inside the water bag. The water bag was
filled with degassed water. The transducer was placed
above the gel phantom. The distance of the transducer
from the phantom was such that the beam focus was
placed in the middle of the gel phantom. The phantom
was wrapped around by the GPFLEX coil (USA in-
struments, Cleveland, OH, USA) to perform all the
imaging studies.
FUS system
The effectiveness of the system was evaluated by creat-
ing lesions in polyacrylamide gel phantom (ONDA
Corporation, Sunnyvale, CA, USA). The FUS system
consists of an RF amplifier (RFG 750W, JJA instruments,
Seattle, WA, USA) and a spherical transducer made
from piezoelectric ceramic (Sonic Concepts, USA). The
transducer operates at 1.14 MHz and has focal length of
10 cm and diameter of 3 cm. The acoustical power of
20 W was applied in continuous mode for 60 s. With
20 W/60 s, the goal was to get temperature maps and
test the MR thermometry without damaging the gel
permanently. In another exposure that creates lesions,
the power used was 30 W for 30 s. With this transducer,
Fig. 1 The existing robotic system dedicated for the brain
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and focal depth for 30 W, lesions are created with a 20-s
exposure or higher. The heating of the system was eval-
uated in the gel phantom. Degassed water was placed
between the transducer, water bag, and the gel phan-
tom, thus providing good acoustical coupling between
the gel phantom and the FUS transducer. The attenu-
ation of the gel as reported by the manufacturer was
0.6 dB/cm at 1 MHz [13].
MR imaging
The robotic FUS system was tested in a 1.5-T MR
system (Signa, General Electric, Fairfield, CT, USA)
using a lumbar spine coil (USA instruments, Cleveland,
OH, USA).
MR thermometry
The temperature elevation during FUS exposures was
estimated using the proton resonance frequency (PRFS)
shift method [14]. This method relates the phase shift
derived from the frequency shift of the MR signal due to
the local temperature elevation (ΔT). This relationship is
described by the following:
ΔΤ ¼ φ Tð Þ−φ T0ð Þ
γαΒ0TE
; ð1Þ
where φ(T) and φ(T0) are the absolute phases of the
MR signal at a starting and final temperature T and T0,
respectively; γ is the gyromagnetic ratio; α is the PRF
change coefficient (0.01 ppm/°C); B0 is the magnetic
field strength; and TE is the echo time.
The spoiled gradient echo sequence (SPGR) was used
for thermometry: repetition time (TR) 38.5 ms, TE
20 ms, bandwidth (BW) 15 kHz, matrix 128 × 128, slice
thickness: 10 mm, and number of excitations (NEX): 1.
The temporal resolution of thermometry was about 12 s.
Phase maps were reconstructed by calculating the phase
on a pixel-by-pixel basis after combining pixel data from
real and imaginary channels. Although the scanner was
capable of producing directly phase image reconstruc-
tions, the applied intra-scan gradient non-linearity
corrections induce phase interpolation problems. All of
the image processing was performed with custom-made
software developed in MATLAB (MathWorks, Natick,
USA). Temperature color-coded maps were produced by
adjusting the color map (blue to red) for a range of mini-
mum to maximum region of interest (ROI) temperature.
Figure 4 shows the flowchart of the software that esti-
mates temperature using the PRFS method.
High-resolution MR imaging was performed to visualize
the FUS lesions in the gel phantom using T2-weighted fast
spin echo (FSE) sequence (imaging parameters, TR
2500 ms, TE 60 ms, slice thickness 3 mm, matrix 256 ×
256, field of view (FOV) 16 cm, NEX 3, and echo train
length (ETL) 8).
Results
Figure 5 shows the MR image using T2-weighted (T2-W)
FSE of the coupling to the gel of the robotic system.
In this image, the transducer-water bag-gel phantom
Fig. 3 The concept of using the modified robotic system for access
to the fibroids
Fig. 2 The developed coupling that can be used for a top-to-bottom access of ultrasound to targets
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arrangement is shown demonstrating the excellent coup-
ling to the gel phantom.
Figure 6 shows the axial temperature maps produced
by this transducer. The acoustical power of 20 W was
applied for 60 s. During the first five images, the FUS
transducer was activated. Having observed the focal
beam in a plane perpendicular to the transducer face,
the next step was to evaluate the temperature maps in a
plane parallel to the transducer face. Figure 7 shows the
coronal temperature maps produced by this transducer.
The acoustical power of 20 W was applied for 60 s.
During the first five images, FUS was activated.
Figure 8 shows the MR images (using T2-W FSE) of
three discrete thermal lesions created in the gel phantom
by moving the X stage of the robotic system. The acous-
tical power used was 30 W for 30 s. The spatial step
between lesions was 5 mm. With the transducer and
focal depth with a 30 W and 30 s exposure, the lesion
Fig. 4 Software flowchart for estimating MR thermometry
Fig. 5 MR image using T2-W FSE of the coupling to the gel of the robotic system
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width is 3.3 mm, and the lesion length is 24 mm (max-
imum temperature recorded was 82 °C). With 60 s expos-
ure and 30 W, the lesion width is 4.2 mm and the lesion
length is 28.4 mm (maximum temperature recorded was
94 °C). At higher power, the lesion size does not change
much since conduction carries the heat away. Also, a
higher power will cause the temperature to exceed 100 °C
(tissue boiling point). Figure 9 shows the MR image (using
T2-W FSE) of the three discrete thermal lesions of Fig. 8
in axial plane demonstrating the penetration deep in the
gel (plane perpendicular to the transducer face).
Figure 10 shows the MR images (using T2-W FSE)
of four overlapping thermal lesions created in the gel
phantom by moving the X and Y stages of the robotic
system in a 2 × 2 square grid. The acoustical power
used was 30 W for 30 s. The spatial step between
lesions was 3 mm. Because the width of the lesion is
close to 3 mm (see Fig. 8), then to get overlapping
lesions, the step size had to be 3 mm. This figure
clearly demonstrates the effectiveness of the position-
ing device for creating large lesions for the purpose of
thermal ablation.
Fig. 6 Axial temperature maps produced by this transducer in a plane perpendicular to the face of the transducer. The acoustical power of 20 W
was applied for 60 s
Fig. 7 Coronal temperature maps produced by this transducer in a plane parallel to the face of the transducer. The acoustical power of 20 W was
applied for 60 s
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Discussion
Our study was inspired by several clinical trials that
have shown that MRgFUS destroys fibroids [6, 7]. In
these studies, the FUS transducer is placed in a water
container which is integrated in the MRI table. The
coupling with this technology is bottom to top, and the
patient sits lying on the table in the prone position.
The focal beam with the existing technologies is moved
using phased-array technology which is very compli-
cated and expensive. In this study, we presented an
alternative technology of MRgFUS which is based on
mechanical movement of a single-element spherically
focused transducer. The proposed technology is simpler
and cost-effective. The coupling to the target is top to
bottom, and the patient may sit in supine position on
the table. The major challenge of this technology is the
coupling of the transducer to the target. This challenge
has already been solved by several studies. The team of
Theraclion “makes” a contact to the thyroid or to the
breast [15] with a transducer placed on the top of the
target reporting a more comfortable patient placement.
This same concept was shown in another study per-
formed by our group [16].
The major advantage of the proposed robot is that
the patient can be placed on the MRI table in supine
position. In the current systems, the patients are placed
in the prone position. Since sometimes the treatment
procedure can be long, lasting up to 3 hours per session
[17, 18], the proposed system could provide better
comfort for the patients. Additionally, the proposed
system can access multiple anatomical locations.
Based on the American Society for Testing and Materials
(ASTM) document F2503 described by Stoianovici et al.
[19], the proposed system is classified as MRI-conditional
because of the use of the FUS transducer, piezoelectric
motors, and optical encoders. The piezoelectric motors,
the transducer, and the optical encoders require the use of
electricity and therefore, the system is MRI-conditional.
Pneumatic systems [19] on the other hand are classified as
MRI safe, because no electricity is used.
Fig. 8 MR images (using T2-W FSE) of three discrete thermal lesions created in the gel phantom by moving the X stage of the robotic system.
The acoustical power used was 30 W for 30 s. The spatial step between lesions was 5 mm
Fig. 9 MR image (using T2-W FSE) of the three discrete thermal lesions of Fig. 7 in axial plane demonstrating the penetration deep in the gel
(plane perpendicular to the transducer face)
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Conclusions
The proposed technology is a continuation of other
MRgFUS technologies designed by our group for various
applications. Such system were developed for brain ab-
lation using three Cartesian axes [12], prostate ablation
using one linear and one angular axis [20, 21], and
gynecological tumor ablation using one linear and one
angular axis [22].
The FUS system produced lesions in gels successfully.
The length and width of these lesions can be easily con-
trolled by varying the intensity and time of exposure.
These discrete and overlapped lesions were produced
using the X and Y axes. The appearance of these lesions
was demonstrated using MRI and proved that the linear
stages moved with great accuracy. The degree of accuracy
of the linear stages was also demonstrated in other articles
of our group (for example, [12, 20, 21]). In future ex-
periments, we plan to use thicker gel phantoms, in
order to create lesions in a model which is closer to the
size of anatomy involved for the case of fibroids.
In the future, some registration marks should be
placed in the proposed system in order to transfer the
position of the transducer or arm in the MRI images.
Additionally, an appropriate MRI coil should be selected.
Currently, the lumbar spine was used (best option avail-
able to us). Better signal can be received if a dedicated coil
is placed in proximity to the target. The proposed system
which is modular can be easily modified to explore other
applications with a top-to-bottom coupling arrangement
(for example, breast or thyroid cancer). Finally, for better
maneuverability, the proposed robot can be enhanced by
the addition of additional motion stages to reach the per-
formance reported by the FUSBOT robotic system [23].
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